Clinical trials: Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus
A randomized single-blind study with the use of different lancing devices equipped with personal lancets to determine and to compare the amount of capillary blood volume and perceived pain after a single lancing of the fingertip.
- Trial name
- NCT04253431
- Testing
- Droplet lancing device (HTL-Strefa S.A.), Microlet 2 lancing device (Bayer), OneTouch Delicia lancing device (LifeScan)
- Volunteers
- 60 people
- Sponsor
- HTL-Strefa S.A.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Diabetes Mellitus
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.
- Trial name
- NCT00306696
- Testing
- Rosiglitazone, spironolactone, hydrochlorothiazide
- Where
- 46 sites in Belgium, Canada and 12 more
- Volunteers
- 388 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes…
- Trial name
- AMPLITUDE-D (NCT03684642)
- Testing
- Efpeglenatide, Dulaglutide, Background therapy Metformin
- Where
- 45 sites in United States, Hungary and 2 more
- Volunteers
- 908 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
Exenatide twice daily has been studied in Japanese type 2 diabetes patients. A once-weekly version of exenatide is currently being evaluated. Study GWBW is the first study of exenatide once weekly in Japanese patients.
- Trial name
- NCT00612794
- Testing
- exenatide once weekly
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02479022
- Testing
- Insulin 320, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- NCT06221969
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 197 sites in United States, Argentina and 6 more
- Volunteers
- 1,024 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
Investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to…
- Trial name
- S019 (NCT00393705)
- Testing
- Insulin Biphasic Aspart 30/70, insulin lispro LM, insulin lispro MM
- Where
- 9 sites in Croatia, Poland and 3 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Type 2 Diabetes
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes.
- Trial name
- NCT07271251
- Testing
- Oral semaglutide
- Where
- 15 sites in Japan
- Volunteers
- 267 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D).
- Trial name
- NCT06403761
- Testing
- Semaglutide, Cagrilintide
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT02053116
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Diabetes Mellitus Type 2
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
- Trial name
- NCT07020949
- Testing
- THDBH120 injection
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes Mellitus Type 2, Crestor, Rosuvastatin
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
- Conditions
- Diabetes Mellitus Type 2, Crestor, Rosuvastatin, LDL Cholesterol, Observational
- Trial name
- NCT00233649
- Where
- 222 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Dyslipidemia
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
- Trial name
- NCT00490178
- Testing
- Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Solvay Pharmaceuticals